共 18 条
[1]
[2]
[3]
[4]
[5]
[6]
[7]
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial[J] The Lancet 2009,
[8]
Pooled Analyses of Effects on C-Reactive Protein and Low Density Lipoprotein Cholesterol in Placebo-Controlled Trials of Ezetimibe Monotherapy or Ezetimibe Added to Baseline Statin Therapy[J] Thomas A. Pearson;Christie M. Ballantyne;Enrico Veltri;Arvind Shah;Steven Bird;Jianxin Lin;Elizabeth Rosenberg;Andrew M. Tershakovec The American Journal of Cardiology 2009,
[9]
Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes[J] Christopher P. Cannon;Robert P. Giugliano;Michael A. Blazing;Robert A. Harrington;John L. Peterson;Christine McCrary Sisk;John Strony;Thomas A. Musliner;Carolyn H. McCabe;Enrico Veltri;Eugene Braunwald;Robert M. Califf American Heart Journal 2008,
[10]
Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin[J] OsamahHussein;LiLiaMinasian;YaroslavItzkovich;KarinaShestatski;LizoraSolomon;JamalZidan British Journal of Clinical Pharmacology 2008,

